Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

NCT ID: NCT05635045

Last Updated: 2025-07-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-08
• Study Completion Date: 2024-06-12

Brief Summary

This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan.

Ten previously scanned subjects re-consented to undergo another 124I-evuzamitide PET scan. Demographic, clinical and phenotypic data were collected to characterize potential changes since their previous scans.

Detailed Description

Transthyretin cardiac amyloidosis (ATTR-CA) causes progressive heart disease that is often overlooked. It harms the heart muscle because the unstable, unfurled amyloid proteins fold up into large pieces that get caught in between layers of heart tissue, causing amyloid deposits. The earlier it is detected, the better for the patient.

There is a need to improve the early diagnosis of this disease because echocardiography (sonograms of the heart) and cardiac MRI are not useful enough for this. There is an X-ray of the heart using a compound called PYP that can detect amyloid deposits earlier than ultrasound images or clinical signs, but it's not clear how early it does so. Also, it can't detect amyloid deposits outside the heart, which causes lots of pain and suffering in people with this disease.

In the first phase of this study the radiation compound, evuzamitide, was shown to detect amyloidosis in the heart of selected subjects. So, the investigators used it to detect potential therapeutic changes in 10 subjects undergoing treatment for Transthyretin Amyloidosis.

Changes in the uptake of evuzamitide were compared between subjects treated on stabilizer only, subjects treated on silencer only and subjects treated with two different combinations of stabilizer plus silencer

Conditions

Transthyretin Amyloidosis

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Stabilizer Only

Subjects treated with tafamidis selected to re-scan to determine the change over time in Evuzamitide uptake

Group Type: ACTIVE_COMPARATOR

I 124-Evuzamitide

Intervention Type: DRUG

Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Silencer Only

Subjects treated with vutrisiran selected to re-scan to determine the change over time in Evuzamitide uptake

Group Type: ACTIVE_COMPARATOR

I 124-Evuzamitide

Intervention Type: DRUG

Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Stabilizer and Silencer (tafamidis + patisiran)

Subjects treated with tafamidis and patisiran selected to re-scan to determine the change over time in Evuzamitide uptake

Group Type: ACTIVE_COMPARATOR

I 124-Evuzamitide

Intervention Type: DRUG

Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Stabilizer and Silencer (vutrisiran + diflunisal)

Subjects treated with vutrisiran and diflunisal selected to re-scan to determine the change over time in Evuzamitide uptake

Group Type: ACTIVE_COMPARATOR

I 124-Evuzamitide

Intervention Type: DRUG

Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Interventions

I 124-Evuzamitide

Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging

Intervention Type: DRUG

Other Intervention Names

Attralus AT-01

Eligibility Criteria

Inclusion Criteria

1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.

2. Were enrolled in the initial pilot using 124I-Evuzamitide, on ATTR stabilizer and/or silencer therapy. Able to understand and sign the informed consent document after the nature of the study has been fully explained.

3. TTR genotype shown to be either Val122Ile or wild type.

1. Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements.

2. Were enrolled in the initial pilot using 124I-Evuzamitide, on ATTR stabilizer and/or silencer therapy. Able to understand and sign the informed consent document after the nature of the study has been fully explained.

3. TTR genotype shown to be either Val122Ile or wild type.

The presence of any of the following excludes eligibility for enrollment in this study:

1. Primary amyloidosis (AL) or secondary amyloidosis (AA).

2. Active malignancy or non-amyloid disease with expected survival of less than 1 year.

3. Heart failure, in the opinion of the investigator, primarily caused by something other than amyloidosis.

4. Ventricular assist device.

5. Impairment from stroke, injury or other medical disorder that precludes participation in the study.

6. Disabling dementia or other mental or behavioral disease.

7. Enrollment in a clinical trial not approved for co-enrollment.

8. Continuous intravenous inotropic therapy.

9. Inability or unwillingness to comply with the study requirements.

10. Chronic kidney disease requiring hemodialysis or peritoneal dialysis.

11. Patients taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation.

12. Other reason that would make the subject inappropriate for entry into this study.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 105 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Attralus, Inc.

INDUSTRY

Sponsor Role: collaborator

Columbia University

OTHER

Sponsor Role: lead

Responsible Party

Mathew S. Maurer, MD

Arnold and Arlene Goldstein Professor of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mathew Maurer, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University

Locations

Columbia University Irving Medical Center

New York, New York, United States

Countries

United States

References

Smiley DA, Einstein AJ, O'Gorman KJ, Santana D, Teruya S, Chan N, Nalbandian A, Poterucha TJ, Helmke ST, Mintz A, Goldner K, Sekulic M, Mirabal A, Cuomo MO, Guadalupe S, De Los Santos J, Paulino ME, Mateo KA, Rodriguez CM, Jimenez M, Wardhere A, Bampatsias D, Castillo M, Peng B, Maurer MS. Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography. JACC Cardiovasc Imaging. 2025 Jul;18(7):799-811. doi: 10.1016/j.jcmg.2025.01.018. Epub 2025 May 28.

Reference Type: DERIVED

PMID: 40439628 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

AAAU0561

Identifier Type: -

Identifier Source: org_study_id